FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2206974328> ?p ?o ?g. }

• W2206974328 abstract "INfeCTIouS rISk of bIologICal drugS VerSuS CoNVeNTIoNal SySTemIC TreaTmeNTS IN moderaTe To SeVere pSorIaSIS S. Couderc; R. Bourrel; C. Paul; J.L. Montastruc; M. Lapeyre-Mestre; and A. Sommet UMR 1027, Inserm, Universite Toulouse III, Toulouse, France; Caisse Nationale d’Assurance Maladie Midi-Pyrenees, Toulouse, France; Service de Dermatologie, Centre Hospitalier Universitaire, Toulouse, France; and Pharmacologie Medicale et Clinique, Centre Hospitalier Universitaire, Toulouse, France Introduction: Moderate to severe psoriasis affects about 0.5% of the population. Its management is based on conventional systemic treatments (TSC: phototherapy, acitretin, methotrexate, and cyclosporine) and biological second-line drugs (etanercept, infliximab, ustekinumab, adalimumab, golimumab). Results of studies comparing the infectious risk of TSC and biological drugs are divergent. Objective: To compare the infectious risk associated with biological drugs versus TSC for moderate to severe psoriasis. Material and Methods: We conducted a retrospective cohort in the French Health Insurance Database for the Midi-Pyrenees region from 01/01/2010 to 31/12/2013, with patients treated incidentally for moderate to severe psoriasis. After a 6-month observation period with all patients exposed to TSC, we compared patients exposed to biological drugs (“exposed”) versus TSC (“unexposed”). We performed a Cox model on the first infectious event, for up to 6 months after the last dispensation of psoriasis drug. An infectious event was defined as delivery of any anti-infectious systemic drug or a hospital diagnosis of infection. Results: The 101 “exposed: patients and 788 “unexposed” patients were comparable in terms of socio-demographic data and comorbidities. Considering the first infectious event over a period of 2 years, no significant difference was found between “exposed” and “unexposed” (HR = 0.94; 95% CI, 0.71–1.22; P = 0.62). Being a woman (HR = 1.23), benefit from the Universal Health Coverage (HR = 1.44), suffering from chronic hepatitis B or C (HR = 2.74), history of neoplasia (HR = 1.70), a previous infectious event during the observation period (HR = 1.74), and the number of drugs consumed during the observation period (HR = 1.03) significantly increased the risk of infection. Conclusions: We did not reveal any difference in infection risk between the TSC and biological drugs in the management of moderate to severe psoriasis. This risk appears constant the first 2 years of use." @default.
• W2206974328 created "2016-06-24" @default.
• W2206974328 creator A5004027720 @default.
• W2206974328 creator A5020129995 @default.
• W2206974328 creator A5037883943 @default.
• W2206974328 creator A5043204548 @default.
• W2206974328 creator A5050870063 @default.
• W2206974328 creator A5069068175 @default.
• W2206974328 date "2015-08-01" @default.
• W2206974328 modified "2023-10-01" @default.
• W2206974328 title "Infectious risk of biological drugs versus conventional systemic treatments in moderate to severe psoriasis" @default.
• W2206974328 doi "https://doi.org/10.1016/j.clinthera.2015.05.020" @default.
• W2206974328 hasPublicationYear "2015" @default.
• W2206974328 type Work @default.
• W2206974328 sameAs 2206974328 @default.
• W2206974328 citedByCount "0" @default.
• W2206974328 crossrefType "journal-article" @default.
• W2206974328 hasAuthorship W2206974328A5004027720 @default.
• W2206974328 hasAuthorship W2206974328A5020129995 @default.
• W2206974328 hasAuthorship W2206974328A5037883943 @default.
• W2206974328 hasAuthorship W2206974328A5043204548 @default.
• W2206974328 hasAuthorship W2206974328A5050870063 @default.
• W2206974328 hasAuthorship W2206974328A5069068175 @default.
• W2206974328 hasConcept C126322002 @default.
• W2206974328 hasConcept C16005928 @default.
• W2206974328 hasConcept C2777138892 @default.
• W2206974328 hasConcept C2777226972 @default.
• W2206974328 hasConcept C2777575956 @default.
• W2206974328 hasConcept C2778496887 @default.
• W2206974328 hasConcept C2778975655 @default.
• W2206974328 hasConcept C2779134260 @default.
• W2206974328 hasConcept C2780132546 @default.
• W2206974328 hasConcept C2780564577 @default.
• W2206974328 hasConcept C2781290027 @default.
• W2206974328 hasConcept C71924100 @default.
• W2206974328 hasConcept C72563966 @default.
• W2206974328 hasConceptScore W2206974328C126322002 @default.
• W2206974328 hasConceptScore W2206974328C16005928 @default.
• W2206974328 hasConceptScore W2206974328C2777138892 @default.
• W2206974328 hasConceptScore W2206974328C2777226972 @default.
• W2206974328 hasConceptScore W2206974328C2777575956 @default.
• W2206974328 hasConceptScore W2206974328C2778496887 @default.
• W2206974328 hasConceptScore W2206974328C2778975655 @default.
• W2206974328 hasConceptScore W2206974328C2779134260 @default.
• W2206974328 hasConceptScore W2206974328C2780132546 @default.
• W2206974328 hasConceptScore W2206974328C2780564577 @default.
• W2206974328 hasConceptScore W2206974328C2781290027 @default.
• W2206974328 hasConceptScore W2206974328C71924100 @default.
• W2206974328 hasConceptScore W2206974328C72563966 @default.
• W2206974328 hasLocation W22069743281 @default.
• W2206974328 hasOpenAccess W2206974328 @default.
• W2206974328 hasPrimaryLocation W22069743281 @default.
• W2206974328 isParatext "false" @default.
• W2206974328 isRetracted "false" @default.
• W2206974328 magId "2206974328" @default.
• W2206974328 workType "article" @default.